Who are we? MS Ventures is the global corporate VC arm of Merck - PowerPoint PPT Presentation

Who are we? MS Ventures is the global corporate VC arm of Merck Serono MS Ventures strategic fund: €110m MS Ventures Entrepreneur Partnership Program: €30m Israel BioIncubator Fund: €10m 1

Decision making process 2

”Project scoring”-table  Yes  No (Medical) need  Yes  No Proprietary  Yes  No Differentiation People Personality Track Record Incentives Potential Market size Competition Pricing / margin Timing Time to market Penetration rate Exclusivity Risk Development Regulatory Market Cost structure Development Inflection points Commercial 3

Where to find us www.ms-ventures.com 4

Backup slides Merck Inhouse Consulting

MS Ventures investment strategy Pharma focus on products, allowing biotech creativity and speed  Strategic assets  Top tier syndicates  Critical path to commercial relevance  A –Teams; Management, Board & SAB  Emphasis on business development  Hands on board support  Tactics follow asset strategy  Interim C roles where needed P  Leverage RD expertise for “wet due diligence”  Nurture assets through active R&D involvement O P  Offer access to manufacturing, screening capabilities etc. at R A cost, at risk and/or in exchange for equity T R F E O  Front-row seat, early due diligence, preferred relationship N L  Foster corporate entrepreneurship within Merck T I  Catalyze exchange and creation of novel of ideas O 6

MS Ventures Global Team Roel Bulthuis Edward Kliphuis Hakan Goker Managing Director Associate Director roel.bulthuis@ms- edward.kliphuis@ms- hakan.goker@ms- ventures.com ventures.com ventures.com AMSTERDAM AMSTERDAM AMSTERDAM Alicia Irurzun-Lafitte Jasper Bos Associate Director alicia.irurzun-lafitte jasper.bos@ms- @ms-ventures.com ventures.com BOSTON GENEVA Laila Gharzai Simone Botti Nilesh Kumar Head of Israel Analyst Director Incubator Fund laila.gharzai@ms- nilesh.kumar@ms- simone.botti@ms- ventures.com ventures.com ventures.com TEL AVIV AMSTERDAM BOSTON 7

MS Ventures at a glance Investing in Innovation MS Ventures strategic fund: €110m MS Ventures Entrepreneur Partnership Program: €30m Israel BioIncubator Fund: €10m 8

MS Ventures is an active early stage investor Hands-on approach to the building of companies Top 20 early stage VCs 2012 - 2013 1 Strategic investors Investor Financings Total ($m) Average ($m) #  MSV supports portfolio companies 1 MS Ventures* 11 $71.2 $6.5 directly and through continued 2 OrbiMed Advisors 10 $158.5 $15.9 interaction with relevant Merck 3 Novartis* 9 $188.0 $20.9 Serono experts 4 Novo A/S* 9 $157.9 $17.6  Takes an active role in the 5 Third Rock Ventures 8 $274.2 $34.3 refinancing processes of our 6 Polaris Venture part. 7 $114.9 $16.4 companies 7 MPM Capital 7 $136.0 $19.4 8 5AM Ventures 7 $195.0 $27.9  Financing plans are structured 9 SR One* 7 $114.0 $16.3 around the critical path towards 10 Atlas Venture 6 $44.2 $7.4 proving commercial relevance 11 Flagship Ventures 6 $173.5 $28.9  Aims to define relevant datapoints 12 Sofinnova Ventures 5 $190.5 $38.1 on that path as a basis for 13 New Enterprise 5 $135.9 $27.2 refinancing decisions 14 Canaan Partners 5 $113.5 $22.7  Places significant emphasis on the 15 Fidelity 5 $80.4 $16.1 quality of our management teams, 16 Pfizer Inc.* 5 $128.4 $25.7 Boards and Scientific Advisory 17 SV Life Sciences 5 $86.7 $17.3 Boards and dedicate a significant 18 Hatteras Venture 5 $57.0 $11.4 amount of our time to finding the 19 Abingworth mgmt 4 $119.3 $29.8 best candidates for these positions 20 Connecticut Innov. 4 $8.5 $2.1 1 Number of Seed- and Series A investments completed in 2012 and 2013. Source: BioCentury BCIQ 9 2 Source: PwC Moneytree 2012; NVCA; numbers are for all Life Sciences deals, inc. diagnostics and agro

MSV financing checklist Focus on differentiation, need and people  Unique science  Proprietary technology  Differentiation  Commercial relevance  Medical need  Risk  People  Pricing model 10

Show me that…my product works better  Really?  How?  Better than what?  Better efficacy?  Better safety?  How can I test that?  When can I test that?  Will I be rewarded for it? 11

Move to trash  „This mechanism is unique, biologically“  „Lowering COGS of mAbs in the ONC  „We see no side effects at all“ field significantly“  „My professor has been working on this  „We can significantly reduce the risks of for 20 years“ drug development“  „We have a highly specific siRNA, just  „We‘re the only ones in the world, there is need to solve delivery“ no competion“ 12